PROMETHEUS BIOSCIENCES INC (RXDX) Stock Price & Overview
NASDAQ:RXDX • US74349U1088
Current stock price
The current stock price of RXDX is 199.92 USD. Today RXDX is up by 0.09%. In the past month the price increased by 3.62%. In the past year, price increased by 684.31%.
RXDX Key Statistics
- Market Cap
- 9.559B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.52
- Dividend Yield
- N/A
RXDX Stock Performance
RXDX Stock Chart
RXDX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to RXDX. When comparing the yearly performance of all stocks, RXDX is one of the better performing stocks in the market, outperforming 99.86% of all stocks.
RXDX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to RXDX. RXDX has a great financial health rating, but its profitability evaluates not so good.
RXDX Earnings
RXDX Forecast & Estimates
15 analysts have analysed RXDX and the average price target is 198.9 USD. This implies a price decrease of -0.51% is expected in the next year compared to the current price of 199.92.
For the next year, analysts expect an EPS growth of -16.9% and a revenue growth -69.44% for RXDX
RXDX Groups
Sector & Classification
RXDX Financial Highlights
Over the last trailing twelve months RXDX reported a non-GAAP Earnings per Share(EPS) of -3.52. The EPS decreased by -26.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
RXDX Ownership
RXDX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.8 | 388.432B | ||
| AMGN | AMGEN INC | 16.04 | 197.413B | ||
| GILD | GILEAD SCIENCES INC | 16.4 | 179.993B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.21 | 119.226B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.95 | 78.843B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.01 | 41.564B | ||
| INSM | INSMED INC | N/A | 30.069B | ||
| BIIB | BIOGEN INC | 11.29 | 26.644B | ||
| NTRA | NATERA INC | N/A | 26.624B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.95 | 23.498B | ||
| MRNA | MODERNA INC | N/A | 20.758B | ||
| EXAS | EXACT SCIENCES CORP | 340.74 | 19.77B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.798B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RXDX
Company Profile
Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 97 full-time employees. The company went IPO on 2021-03-11. The firm discovers, develops and commercializes therapeutic products for the treatment of immune-mediated diseases, inflammatory bowel disease. Its precision medicine platform, Prometheus360, includes gastrointestinal bioinformatics databases and sample biobanks, to identify therapeutic targets, develop therapeutic candidates to engage those targets, and develop genetics-based diagnostic tests designed to identify patients to respond to its therapeutic candidates. Its lead product candidate, PRA023, is a humanized IgG1 monoclonal antibody (mAb) that has been shown to block the tumor necrosis factor (TNF). Its second product candidate, PRA052, is an anti-CD30L mAb. The CD30L-CD30 co-stimulatory pathway has been implicated in IBD by genetic, preclinical and human translational data. Its PR1100 program targets the receptor for a pro-inflammatory cytokine that has been linked to multiple immune-mediated diseases.
Company Info
IPO: 2021-03-11
PROMETHEUS BIOSCIENCES INC
3050 Science Park Road, #342
San Diego CALIFORNIA 92121 US
CEO: Mark C. McKenna
Employees: 97
Phone: 18584224300.0
PROMETHEUS BIOSCIENCES INC / RXDX FAQ
Can you describe the business of PROMETHEUS BIOSCIENCES INC?
Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 97 full-time employees. The company went IPO on 2021-03-11. The firm discovers, develops and commercializes therapeutic products for the treatment of immune-mediated diseases, inflammatory bowel disease. Its precision medicine platform, Prometheus360, includes gastrointestinal bioinformatics databases and sample biobanks, to identify therapeutic targets, develop therapeutic candidates to engage those targets, and develop genetics-based diagnostic tests designed to identify patients to respond to its therapeutic candidates. Its lead product candidate, PRA023, is a humanized IgG1 monoclonal antibody (mAb) that has been shown to block the tumor necrosis factor (TNF). Its second product candidate, PRA052, is an anti-CD30L mAb. The CD30L-CD30 co-stimulatory pathway has been implicated in IBD by genetic, preclinical and human translational data. Its PR1100 program targets the receptor for a pro-inflammatory cytokine that has been linked to multiple immune-mediated diseases.
What is the current price of RXDX stock?
The current stock price of RXDX is 199.92 USD. The price increased by 0.09% in the last trading session.
What is the dividend status of PROMETHEUS BIOSCIENCES INC?
RXDX does not pay a dividend.
What is the ChartMill technical and fundamental rating of RXDX stock?
RXDX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What do analysts say about PROMETHEUS BIOSCIENCES INC (RXDX) stock?
15 analysts have analysed RXDX and the average price target is 198.9 USD. This implies a price decrease of -0.51% is expected in the next year compared to the current price of 199.92.
Can you provide the number of employees for PROMETHEUS BIOSCIENCES INC?
PROMETHEUS BIOSCIENCES INC (RXDX) currently has 97 employees.
What is the market capitalization of RXDX stock?
PROMETHEUS BIOSCIENCES INC (RXDX) has a market capitalization of 9.56B USD. This makes RXDX a Mid Cap stock.